GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3332)

  • GC80918 structure
    GC80918dCBP-30
    Purity: >98.00%

    dCBP-30 is an orally active, selective and dual-acting CBP/p300 PROTAC degrader with DC 50 values of 0.05 nM (CBP) and 0.04 nM (p300), respectively.

  • GC80920 structure
    GC80920PROTAC PARP2 degrader-1
    CAS: 2925182-32-5
    Purity: >95.50%

    PROTAC PARP2 degrader-1 is an orally active PARP2 PROTAC degrader with a DC 50 of 2 μM.

  • GC80922 structure
    GC80922PROTAC HDAC6 degrader 7
    Purity: >98.00%

    PROTAC HDAC6 degrader 7 is an orally active, highly efficient, and selective PROTAC degrader targeting histone deacetylase 6 ( HDAC6 ) ( IC 50 = 118 nM).

  • GC80928 structure
    GC80928NP1192
    CAS: 2966791-41-1
    Purity: >99.00%

    NP1192 is a potent, selective PROTAC NAT10 degrader.

  • GC80943 structure
    GC80943KT-474 hydrochloride
    CAS: 2751703-31-6
    Purity: >98.00%

    KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects.

  • GC80946 structure
    GC80946PROTAC JAK1/2 degrader-1
    Purity: >99.00%

    PROTAC JAK1/2 degrader-1 is an orally active JAK1 / JAK2 PROTAC degrader, with DC 50 values of 1.4 μM and 0.92 μM against JAK1 and JAK2, respectively.

  • GC81022 structure
    GC81022JWZ-8-103
    CAS: 3110272-60-8
    Purity: >98.00%

    JWZ-8-103 is an orally active analog of PRLX-93936 and a molecular glue targeting TRIM21.

  • GC81024 structure
    GC81024PROTAC RNF4 degrader-1
    Purity: >98.00%

    PROTAC RNF4 degrader-1 is a RNF4 PROTAC degrader ( K d = 64.5 nM) that degrades RNF4 via the ubiquitin-proteasome system.

  • GC81026 structure
    GC81026PROTAC SKP2 Degrader-1
    CAS: 3120650-15-6
    Purity: >99.50%

    PROTAC SKP2 Degrader-1 is a PROTAC degrader targeting SKP2, with a K d value of 6.28 μM.

  • GC81027 structure
    GC81027PROTAC HIF-1α degrader-2
    CAS: 3095636-64-6
    Purity: >98.00%

    PROTAC HIF-1α degrader-2 is a highly efficient and selective PROTAC degrader targeting HIF-1α. PROTAC HIF-1α degrader-2 promotes HIF-1α degradation via the ubiquitin-proteasome pathway by facilitating the formation of a HIF-1α/VHL ternary complex.

  • GC81040 structure
    GC81040VVD 065
    CAS: 3034876-85-9
    Purity: >99.50%

    VVD 065 is an orally active KEAP1 -dependent NRF2 molecular glue degrader with a KEAP1 K D of 65 nM.

  • GC81041 structure
    GC81041GP262
    CAS: 3107761-81-6
    Purity: >98.50%

    GP262 is a PI3K/mTOR PROTAC degrader targeting PI3Kγ, PI3Kα and mTOR with DC 50 values of 42.23 nM, 227.4 nM and 45.4 nM, respectively in MDA-MB-231 cells.

  • GC81297 structure
    GC81297DFCI-002-06
    CAS: 3092208-36-8
    Purity: >98.00%

    DFCI-002-06 is an orally active dual-target HCK/BTK PROTAC degrader with DC₅₀ values for HCK and BTK of 1.3 and 4.5 nM respectively.

  • GC81304 structure
    GC81304GW296115
    CAS: 118458-58-5
    Purity: >98.50%

    GW296115 is a multi-target inhibitor with the following IC 50 values against its targets: 8.4 nM for BRSK2, 21 nM for BRSK1, 1.8 μM for PDGFRβ, 5.5 nM for STK17B/DRAK2, 28 nM for DRAK1, 20 nM for PHKG1, and 89 nM for DCAMKL3.

  • GC81305 structure
    GC81305Tyrosine kinase-IN-11
    CAS: 3031972-21-8
    Purity: >98.50%

    Tyrosine kinase-IN-11 (Compound 4b) is a tyrosine kinase inhibitor.

  • GC81306 structure
    GC81306PRT-060318 dihydrochloride
    CAS: 3032567-93-1
    Purity: >98.50%

    PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC 50 of 3 nM.

  • GC81312 structure
    GC81312PARP1/c-Met-IN-3
    CAS: 3123529-62-1
    Purity: >98.00%

    PARP1/c-Met-IN-3 (Compound L19) is a selective c-Met and PARP1 inhibitor, with an IC 50 of 5.4 nM against c-Met and an IC 50 of 3.7 nM against PARP1.

  • GC81316 structure
    GC81316RC148
    Purity: >99.50%

    RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1.

  • GC81320 structure
    GC81320Papaveroline
    CAS: 574-77-6
    Purity: >98.00%

    Papaveroline is a Fyn tyrosine kinase inhibitor, Na +,K + -ATPase inhibitor with an IC 50 of 0.20 mM, Mg 2+ -ATPase inhibitor, K + -activated pNPPase inhibitor with an IC 50 of 1.51 mM, and apoptosis inducer [1] [2] [3] . Papaveroline binds to the active site of Fyn tyrosine kinase and forms stable interactions with pocket amino acid residues [1] . Papaveroline induces cell apoptosis, produces pycnotic and fragmented cell nuclei, and does not reduce intracellular ATP levels [3] . Papaveroline is a dopamine-derived neurotoxin candidate associated with the pathogenesis of Parkinson's disease [3] . Papaveroline can be used in the research of Alzheimer's disease and Parkinson's disease [3] .

  • GC81323 structure
    GC81323PDGFRA/CAIX/XII-IN-1
    Purity: >98.00%

    PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC 50 of 20 nM against PDGFRA, a K i of 93.3 nM against CA IX, and a K i of 80.0 nM against CA XII.

  • GC81324 structure
    GC81324FGF7p
    CAS: 2758194-43-1
    Purity: >99.00%

    FGF7p is a small molecule peptide and a potential bladder protector.

  • GC81328 structure
    GC81328GZD-552
    Purity: >98.00%

    GZD-552 is a potent orally active FAK inhibitor with a human FAK IC 50 of 5.8 nM.

  • GC81335 structure
    GC81335MST3-IN-1 TFA
    Purity: >99.00%

    MST3-IN-1 TFA (Compound LD-1) is a selective and orally active MST3 inhibitor, with an IC 50 of 122.4 nM.

  • GC81350 structure
    GC81350THR-123 TFA
    Purity: >99.50%

    THR-123 TFA is an orally active ALK3 peptide agonist.